Acute fibrinous and organizing pneumonia
A report of 13 cases in a tertiary university hospital

Rita Gomes (MD)a,b,*, Eva Padrão (MD)c, Hans Dabó (MD)c, Filipa Soares Pires (MD)c, Patrícia Mota (MD)c,d, Natália Melo (MD)c, José Miguel Jesus (MD)d,e, Rui Cunha (MD)d,e, Susana Guimarães (MD)d,f, Conceição Souto Moura (MD)d,f, António Morais (MD, PhD)c,d

Abstract
Introduction Acute fibrinous and organizing pneumonia (AFOP) is a rare diffuse pulmonary disease, but it is not yet known whether it is a distinct form of interstitial pneumonia or simply a reflection of a tissue sampling issue.

Methods Cross-sectional evaluation of clinical and radiological findings, treatments, and outcomes for patients with histologically confirmed AFOP at a tertiary university hospital between 2002 and 2015.

Results Thirteen patients (7 women, 53.8%) with a mean ± SD age of 53.5 ± 16.1 years were included. The main symptoms were fever (69.2%), cough (46.2%), and chest pain (30.8%). All patients presented a radiological pattern of consolidation and 5 (38.5%) had simultaneous ground-glass areas. Histology was obtained by computed tomography-guided transthoracic biopsy in 61.5% of cases and by surgical lung biopsy in the remaining cases. Several potential etiologic factors were identified. Eight patients (61.5%) had hematologic disorders and 3 had undergone an autologous hematopoietic cell transplant. Two (15.4%) had microbiologic isolates, 5 (38.4%) had drug-induced lung toxicity, and 2 (15.4%) were classified as having idiopathic AFOP. In addition to antibiotics and diuretics used to treat the underlying disease, the main treatment was corticosteroids, combined in some cases with immunosuppressants. Median survival was 78 months and 6 patients (46.2%) were still alive at the time of analysis.

Conclusion Our findings for this series of patients confirm that AFOP is a nonspecific reaction to various agents with a heterogeneous clinical presentation and clinical course that seems to be influenced mainly by the severity of the underlying disorder.

Abbreviations: AFOP = acute fibrinous and organizing pneumonia, IMV = invasive mechanical ventilation.

Keywords: acute fibrinous and organizing pneumonia (AFOP), etiology, treatment

1. Introduction
Acute fibrinous and organizing pneumonia (AFOP) is a histological pattern characterized predominantly by the presence of intra-alveolar fibrin in the form of fibrin “balls” within the alveolar spaces, with a patchy distribution, and organizing pneumonia.[1,2] It was first described in 2002 by Beasley et al.[1] in a series of 17 patients. Since then, there have been essentially isolated reports describing diverse causes and clinical courses.[3–6] Consequently, whether AFOP is a distinct pattern of interstitial pneumonia or whether it simply reflects a tissue sampling issue remains to be elucidated.[2]

A variety of causes have been linked to AFOP, including infections, drugs, immune status, and occupational exposures, but idiopathic cases have also been described. The condition frequently occurs in the context of an underlying disease (Table 1).[1,4–7,12] Data on outcomes also vary due to this diversity, but a significant number of cases have been associated with poor prognosis.[1,18] The real influence of AFOP versus its causes or associated conditions remains to be elucidated.

Given the variability in clinical, radiological, and bronchoalveolar lavage findings, diagnosis requires the detection of characteristic features of AFOP in a lung tissue sample.[1,2,3,13–15] Numerous treatments have been reported for AFOP, but considering the rarity of the condition, together with the diversity of clinical presentations and underlying conditions, there are no standard treatment recommendations.[1,3,5,16–19]

The aim of the study was to describe the clinical evaluation and course of patients with a histological diagnosis of AFOP in a tertiary hospital, to report on the treatments prescribed, and to explore prognostic factors associated with different outcomes.

2. Methods
2.1. Study design
We performed a cross-sectional study of patients with a histological diagnosis of AFOP evaluated at the Centro Hospitalar São João in Oporto, Portugal, between 2002 and
Our hospital is a tertiary referral center serving patients mostly from the Oporto district and the north of Portugal. The study was approved by the institutional review board at our institution. We analyzed clinical, functional, and radiological features, diagnostic methods, investigations of etiologic factors, and treatments and outcomes.

The histological criteria used were those defined in 2002 by Beasley et al.\(^1\) that is, the presence of intra-alveolar fibrin in the form of fibrin balls within the alveolar spaces in a patchy distribution and organizing pneumonia consisting of intraluminal loose connective tissue within bronchiolo and alveolar ducts. Additional features described include hyperplasia of type II pneumocytes, alveolar septal expansion, and acute and/or chronic inflammation (Fig. 1).

### 2.2. Statistical analysis

We used the Kolmogorov–Smirnov test \((P \geq 0.05)\) to determine the normality of continuous variables and Levene’s test to assess equality of variances. Differences between means were analyzed using the \(t\) test for normally distributed variables. A Kaplan–Meier curve was used for the survival analysis. \(P\) values \(< 0.05\) were considered to be statistically significant. Statistical analyses were performed using IBM SPSS Statistics for Windows, version 19.0.

### 3. Results

We analyzed 13 patients with a histological diagnosis of AFOP treated at our hospital between 2002 and 2015. Seven (53.8\%) were women and 6 (46.2\%) were men. The mean ± SD age (Kolmogorov–Smirnov test, \(P = 0.956\)) was 53.5 ± 16.1 years, and was higher in men (60.8 ± 16.2) than in women (47.1 ± 14.1), although the difference was not statistically significant \((P = 0.131)\). Mean time from onset of symptoms to diagnosis was 43.9 ± 33.0 days. The clinical presentation included fever in 9 patients (69.2\%), cough in 6 (46.2\%), chest pain in 4 (30.8\%), constitutional symptoms in 3 (23.1\%), and dyspnea in 2 (15.4\%). The presentation was acute in 2 patients (15.4\%) and subacute in the remaining 11 (84.6\%). One patient (7.7\%) was asymptomatic.

All patients presented a radiological pattern of consolidation, and 5 (38.5\%) had a consolidation pattern together with ground-glass areas in the high-resolution computed tomography chest scan; the distribution was mostly diffuse random, but 3 patients (23.1\%) showed a diffuse peribronchovascular distribution (Fig. 2). AFOP histology was obtained by computed tomography-guided lung transthoracic biopsy in 8 patients (61.5\%) and by surgical lung biopsy in 5 (38.5\%).

The majority of patients \((n = 8, 61.5\%)\) had hematologic disorders: 4 (30.4\%) had lymphomas (Hodgkin in 3 cases and non-Hodgkin in 1), 2 (15.4\%) had acute leukemia (acute lymphoblastic leukemia and acute myeloid leukemia), 1 (7.7\%)

### Table 1: Possible etiologic and risk factors in acute fibrinous and organizing pneumonia.

| Category                      | Factors                                           |
|-------------------------------|--------------------------------------------------|
| **Autoimmune diseases**       | Polymyositis, Dermatomyositis, Antisynthetase syndrome, Ankylosing spondylitis, Rheumatoid arthritis, Fibromyalgia, Systemic lupus erythematosus, Primary biliary cirrhosis |
| **Infections**                | Haemophilus influenza, Acinetobacter baumannii, Pneumocystis jirovecii, Chlamydia pneumoniae, Whipple’s disease, Respiratory syncytial virus |
| **Drugs**                     | Abacavir, Decitabine, Amiodarone, Statin, Busulfan, Fluorurabine, Bleomycin, Everolimus, Trimethoprim-sulfamethoxazole |
| **Immune status**             | Prolonged corticosteroid therapy, Poorly controlled diabetes mellitus, Alcoholism, Human immunodeficiency virus infection |
| **Hematological disorders**   | Myelodysplastic syndromes, Lymphomas, Acute lymphoblastic leukemia, Acute myeloid leukemia, Allogeneic hematopoietic cell transplant |
| **Occupational exposures**    | Coal mines, Construction, Hair spray, Zoological work |

2015. Our hospital is a tertiary referral center serving patients mostly from the Oporto district and the north of Portugal. The study was approved by the institutional review board at our institution. We analyzed clinical, functional, and radiological features, diagnostic methods, investigations of etiologic factors, and treatments and outcomes.

**Figure 1.** Histologic findings of acute fibrinous and organizing pneumonia: (A) hematoxylin and eosin stain, ×100; (B) hematoxylin and eosin stain, ×200. Alveoli containing fibrin “balls” and some granulation tissue, in a patchy distribution.
had myelodysplastic syndrome, and 1 (7.7%) had multiple myeloma. Three patients (23.1%) with lymphoma had undergone an autologous hematopoietic cell transplant. Two of the patients (15.4%) also had microbiologic isolates, specifically Acinetobacter baumannii and A fumigatus. All 8 patients were receiving medication for their hematologic disorders. However, of all the drugs evaluated, only azacytidine and bleomycin have been linked to AFOP to date.[17,20]

**Table 2**

Clinical characteristics and treatment of AFOP patients.

| Case | Gender | Age (years) | Antecedents                  | Presenting symptoms                        | Time between the presentation and diagnosis (days) | Possible etiologies                                      | Treatment | Outcome                      |
|------|--------|-------------|------------------------------|--------------------------------------------|--------------------------------------------------|--------------------------------------------------------|-----------|-------------------------------|
| 1    | ♀      | 62          | Myelodysplastic syndrome     | Fever and cough                            | 120                                              | Myelodysplastic syndrome Azacytidine                   | Antibiotics, Corticosteroids, MMF, IMV, Suspension of azacytidine, Antibiotics | Death (AFOP progression) |
| 2    | ♂      | 79          | Hodgkin lymphoma             | Fever, dyspnea, and chest pain             | 20                                               | Idiopathic                                             | Antibiotics | Disease resolution             |
| 3    | ♂      | 56          | Hodgkin lymphoma             | Fever and constitutional symptoms          | 38                                               | Hodgkin lymphoma, Bleomycin (Acinetobacter baumannii) | Antibiotics, Corticosteroids, Suspension of bleomycin | Death (lymphoma progression) |
| 4    | ♂      | 32          | Acute lymphoblastic leukemia B | Fever                                      | 12                                               | Acute lymphoblastic leukemia B, S. aureus               | Antibiotics | Disease resolution             |
| 5    | ♂      | 71          | Kidney transplant for IgA nephropathy | Asymptomatic                                      | 60                                              | Corticosteroids, Cyclophosphamide, MMF, Suspension of sirolimus | Antibiotics, Corticosteroids, Suspension of sirolimus | Death (septic shock) |
| 6    | ♂      | 65          | Cough and chest pain         |                                            | 60                                               | Idiopathic                                             | Corticosteroids, Cyclophosphamide | Chronic disease |
| 7    | ♀      | 45          | Community-acquired pneumonia |                                            | 8                                                | Lung abscess (AFOP on periphery of abscess)            | Antibiotics | Disease resolution             |
| 8    | ♀      | 22          | Hodgkin lymphoma, AHCT       | Fever and cough                            | 30                                               | Hodgkin lymphoma                                       | Antibiotics, Corticosteroids, IMV | Death (AFOP progression) |
| 9    | ♂      | 62          | Non-Hodgkin lymphoma, AHCT   | Fever                                      | 20                                               | Non-Hodgkin lymphoma                                   | Antibiotics | Disease resolution             |
| 10   | ♀      | 37          | Invasive ductal carcinoma of breast | Fever, cough, chest pain, dyspnea, and constitutional symptoms | 90                                               | Adjuvant chemotherapy and radiotherapy                 | Antibiotics | Death (Disease resolution)    |
| 11   | ♀      | 61          | Hodgkin lymphoma, AHCT       | Chest pain                                 | 22                                               | Hodgkin lymphoma                                       | Antibiotics, Corticosteroids, IMV | Death (AFOP progression) |
| 12   | ♂      | 52          | Acute myeloid leukemia       | Fever and constitutional symptoms          | 60                                               | Acute myeloid leukemia                                  | Antibiotics | Death (leukemia progression)  |
| 13   | ♂      | 51          | Multiple myeloma, Kidney transplantation, for IgA nephropathy | Cough                                      | 30                                               | Prolonged corticosteroid therapy Eversimilus           | Antibiotics, Suspension of everolimus | Death (hemorrhagic shock) |

AFOP = acute fibrinous and organizing pneumonia, AHCT = autologous hematopoietic cell transplant, IgA = immunoglobulin A, IMV = invasive mechanical ventilation, MMF = mycophenolate mofetil.
The patient with multiple myeloma was being treated with everolimus and prolonged corticosteroid therapy for a kidney transplant performed 7 years earlier.

Another patient (7.7%) had undergone a kidney transplant 6 years earlier and was being treated with sirolimus. Although this drug has never been associated with AFOP, sirolimus can induce a range of adverse respiratory events, and other immunosuppressive macrolides, such as everolimus, have been linked to AFOP.[21,22] In this case, thus, sirolimus was identified as the probable cause of AFOP. One patient (7.7%) had breast cancer and had undergone surgery followed by adjuvant chemotherapy (docetaxel) and radiotherapy. Although neither of these therapies has been linked to AFOP, the co-occurrence of AFOP means that this association must be considered. Two patients (15.4%) were considered to have idiopathic AFOP after an extensive search for possible causes. One patient (7.7%) had AFOP only on the periphery of a lung abscess, and it was considered to be simply a histological feature of this lesion.

Treatment included antibiotics in 11 patients (84.6%), corticosteroids in 10 (76.9%), mycophenolate mofetil in 2 (15.4%), and cyclophosphamide in 2 (15.4%). Drugs suspected to be associated with AFOP were withdrawn. Three patients (23.1%) required invasive mechanical ventilation (IMV) in an intensive care unit.

The median survival according to the Kaplan–Meier curve was ~78 months, and 6 patients (46.2%) were still alive at the time of our analysis. The mean duration of follow-up for these 6 patients was 76.7 ± 54.6 months; 5 (83.3%) had acute disease, and 1 (16.7%) developed chronic disease. Seven patients (53.8%) died. AFOP was the cause of death in 3 cases (42.9%); the other 4 patients (57.1%) died of other causes: lymphoma leukemia progression in 2 cases and septic/hemorrhagic shock in the other 2. The mean time from the onset of symptoms to death due to AFOP progression was 89.3 ± 104.5 days.

Table 2 summarizes the clinical characteristics and treatments administered for the 13 patients.

4. Discussion

Our identification of just 13 cases of histologically confirmed AFOP in a tertiary referral hospital over a period of 14 years confirms the rarity of this entity. The age of the patients was diverse and there was no clear gender difference. A significant number of patients (n=8) had an underlying hematologic disorder, but the majority of patients had several potential causes of AFOP, including drugs and infectious agents. Due to the diversity of conditions and, consequently, treatments, we were unable to identify any specific potentially effective drugs. Clinical outcomes were also diverse, and ranged from resolution to death (53.8% of cases). We were unable to identify prognostic factors due to the small sample size and the significant number of comorbidities and complications during the clinical course of the patients who died.

AFOP is a rare histological pattern of acute lung injury. It is a relatively new entity that requires better clinical and radiologic characterization and the identification of poor outcome markers. Numerous causes have been associated with AFOP to date.[1,4,7,12] In our sample, 8 patients (61.5%) had a hematologic disorder. AFOP has been linked to hematologic disorders in isolated reports and also in the only 2 cases series published to date, although to a considerably lower extend than in our series.[1,6,7,23,24] Our institution is a university hospital with 1100 beds and covers all medical and surgical specialties, with no particular predominance. One possible explanation for the preponderance of hematologic disorders is that these patients may need aggressive chemotherapy, leading to immunosuppression and consequently the risk of opportunistic infections, which are all possible causes of AFOP. We identified several potential etiologic factors, mostly related to infections (A baumannii and A fumigatus) or drug-induced toxicity (azacytidine, bleomycin, everolimus, and sirolimus), in a significant number of cases. To our knowledge, this is the first series of AFOP to report sirolimus as a potential cause of AFOP, and its implication is based on previous reports of an association between AFOP and drugs with similar pharmacologic proprieties.[21,22] We also believe that combined chemoradiotherapy may have been responsible for AFOP in 1 patient because of the co-occurrence in time and the absence of other probable causes. Although there have been reports of idiopathic AFOP,[15,19,25] an exhaustive investigation is critical as etiology seems to be an important determinant of prognosis and consequently of treatment.

The presenting symptoms of AFOP were nonspecific. In our sample, the mean time from onset of symptoms to diagnosis was 43.9 days, which is significantly longer than the 19 days described by Beasley et al.[1] Two patients had symptoms for >60 days. This considerable diagnostic delay may be due to the nonspecific nature of the presenting symptoms, which in many cases overlapped with those of several of the comorbidities observed. AFOP has no pathognomonic or specific radiologic features, although bilateral basal opacities are frequently seen, as are occasional diffuse areas of consolidation, sometimes with bronchovascular bundles.[1,14]

AFOP has no specific treatment and therapeutic strategies vary considerably according to the underlying disease and clinical presentation.[1,3,5,16–19] Coinciding with reports in the literature, the treatments used in our series were diverse. In addition to specific treatments for the underlying disease, such as antibiotics or diuretics, AFOP treatments included mostly steroids, combined in some cases with immunosuppressants, such as cyclophosphamide or mycophenolate mofetil. However, none of the treatments was identified as being particularly beneficial.

In the series described by Beasley et al,[1] 30% of patients required IMV and they all died. In our sample, IMV was used in 23.1% of patients, who all died due to progression of AFOP. This observation would appear to confirm Beasley et al’s[1] suggestion that there are 2 main forms of disease: a fulminant form leading to rapid deterioration and death and another, subacute form, which in some cases may resolve after treatment with corticosteroids. Median survival in our sample was ~78 months. The mortality rate described in the literature is >50%,[1] which coincides with our findings, as 7 (54%) of the patients in our series died. Three of the deaths were due to AFOP progression. Because of the small number of patients, we were unable to isolate any prognostic factors. However, the fact that the 2 patients considered to have idiopathic AFOP had longer survival times deserves some attention, as it could be speculated that it is largely the underlying condition and not AFOP itself that is associated with poor prognosis.

In conclusion, this cohort analysis confirmed that AFOP is a nonspecific reaction to various agents that follows a heterogeneous clinical course, with variable presentations, that seems to be largely influenced by the severity of the underlying disorder.

References

[1] Beasley MB, Franks TJ, Galvin JR, et al. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med 2002;126:1064–70.
Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–48.

Picciucchi S, Dubini A, Tomassetti S, et al. A case of amiodarone-induced acute fibrinous and organizing pneumonia mimicking mesothelioma. Am J Respir Crit Care Med 2015;191:104–6.

Guimarães C, Sanches I, Ferreira C. Acute fibrinous and organising pneumonia. BMJ Case Rep 2012;Published online.

Damas C, Morais A, Moura CS, et al. Acute fibrinous and organizing pneumonia. Revista Portuguesa Pneumologia 2006;12:615–20.

Lee SM, Park JJ, Sung SH, et al. Acute fibrinous and organizing pneumonia following hematopoietic stem cell transplantation. Kor J Int Med 2009;24:156–9.

Dai JH, Li H, Shen W, et al. Clinical and radiological profile of acute fibrinous and organizing pneumonia: a retrospective study. Chin Med J 2015;128:2701–6.

Valim V, Rocha RH, Couto RB, et al. Acute fibrinous and organizing pneumonia and undifferentiated connective tissue disease: a case report. Case Rep Rheumatol 2012;Published online.

Heo JY, Song JY, Noh JY, et al. Acute fibrinous and organizing pneumonia in a patient with HIV infection and Pneumocystis jiroveci pneumonia. Respiriology 2010;15:1259–61.

Jarmous F, Alyaz SZ, Chooate J. Acute fibrinous organising pneumonia: a manifestation of trimethoprim-sulfamethoxazole pulmonary toxicity. BMJ Case Rep 2014;Published online.

Paraskeva M, McLean C, Ellis S, et al. Acute fibrinoid organizing pneumonia after lung transplantation. Am J Resp Crit Care Med 2013;187:1360–8.

Riber A, Llatoj R, Casanova A, et al. Chlamydia pneumoniae infection associated to acute fibrinous and organizing pneumonia. Enfermedades Infecciosas y Microbiologia Clinica 2011;29:632–4.

Santos C, Pradinho F, Catarino A. Acute fibrinous and organizing pneumonia. Revista Portuguesa Pneumologia 2010;16:607–16.

Johkoh T, Fukuoka J, Tanaka T. Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs. Eur J Radiol 2015;84:542–6.

Kobayashi H, Sugimoto C, Kanoh S, et al. Acute fibrinous and organizing pneumonia: initial presentation as a solitary nodule. J Thorac Imaging 2005;20:291–3.

Yokogawa N, Akic DV. Acute fibrinous and organizing pneumonia as a rare presentation of abacavir hypersensitivity reaction. AIDS 2007;21:2116–7.

Vasu TS, Cavallazzi R, Hirani A, et al. A 64-year-old male with fever and persistent lung infiltrate. Resp Care 2009;54:1263–5.

Rapaka V, Hussain MA, Nizzi M, et al. Severe acute fibrinous and organizing pneumonia causing acute respiratory distress syndrome and shock. J Bronchol Interv Pulmonol 2011;18:269–73.

Bhatti S, Hakeem A, Torrealba J, et al. Severe acute fibrinous and organizing pneumonia (APOP) causing ventilatory failure: successful treatment with mycophenolate mofetil and corticosteroids. Resp Med 2009;103:1764–7.

Hankollari E, Saleem S, Jones J, et al. Acute fibrinous and organizing pneumonia: a rare histopathologic variant of bleomycin-induced lung injury. Chest J 2013;144:456A–456A.

Nazer L, Alnajjar T, Salah S, et al. Fatal case of cryptogenic organizing pneumonia associated with everolimus. Ann Saudi Med 2014;34:437–9.

Foucher P, Camus P. Pneumotox online: the drug-induced respiratory disease. See: www.pneumotox.com. Accessed August 19, 2015.

Merrill AL, Smith H. Myelodysplastic syndrome and autoimmunity: a case report of an unusual presentation of myelodysplastic syndrome. Case Rep Hematol 2011;2011:560106.

Kim C. Acute lymphoblastic leukemia presenting with an acute fibrinous and organizing pneumonia. J Resp Dis 2007;28:33–133.

Al-Khouzaie TH, Dawamneh MF, Hazmi AM. Acute fibrinous and organizing pneumonia. Ann Saudi Med 2013;33:301–3.